Susquehanna International Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-950,839
| Closed | -$3.63M | – | 13478 |
|
|
2024
Q1 | $4.11M | Sell |
950,839
-627,762
| -40% | -$2.19M | ﹤0.01% | 3969 |
|
|
2023
Q4 | $4.81M | Buy |
+1,578,601
| New | +$2.97M | ﹤0.01% | 3765 |
|
|
2023
Q3 | – | Sell |
-12,471
| Closed | -$24.1K | – | 13230 |
|
|
2023
Q2 | $31.1K | Sell |
12,471
-308,802
| -96% | -$844K | ﹤0.01% | 11505 |
|
|
2023
Q1 | $861K | Sell |
321,273
-56,519
| -15% | -$272K | ﹤0.01% | 7213 |
|
|
2022
Q4 | $2.05M | Buy |
377,792
+203,830
| +117% | +$1.71M | ﹤0.01% | 4659 |
|
|
2022
Q3 | $2.17M | Buy |
173,962
+109,034
| +168% | +$1.25M | ﹤0.01% | 4746 |
|
|
2022
Q2 | $321K | Sell |
64,928
-34,467
| -35% | -$191K | ﹤0.01% | 9408 |
|
|
2022
Q1 | $755K | Sell |
99,395
-99,341
| -50% | -$942K | ﹤0.01% | 7874 |
|
|
2021
Q4 | $2.03M | Buy |
198,736
+34,290
| +21% | +$437K | ﹤0.01% | 5463 |
|
|
2021
Q3 | $2.21M | Buy |
164,446
+83,653
| +104% | +$1.36M | ﹤0.01% | 5614 |
|
|
2021
Q2 | $1.77M | Sell |
80,793
-52,651
| -39% | -$1.17M | ﹤0.01% | 6192 |
|
|
2021
Q1 | $3.21M | Sell |
133,444
-79,470
| -37% | -$1.85M | ﹤0.01% | 4802 |
|
|
2020
Q4 | $3.83M | Buy |
212,914
+157,546
| +285% | +$2.35M | ﹤0.01% | 3890 |
|
|
2020
Q3 | $640K | Buy |
55,368
+38,358
| +226% | +$633K | ﹤0.01% | 7152 |
|
|
2020
Q2 | $413K | Sell |
17,010
-9,110
| -35% | -$151K | ﹤0.01% | 7769 |
|
|
2020
Q1 | $288K | Buy |
26,120
+16,583
| +174% | +$310K | ﹤0.01% | 8066 |
|
|
2019
Q4 | $252K | Sell |
9,537
-14,561
| -60% | -$341K | ﹤0.01% | 8350 |
|
|
2019
Q3 | $549K | Sell |
24,098
-10,939
| -31% | -$345K | ﹤0.01% | 7094 |
|
|
2019
Q2 | $1.07M | Buy |
+35,037
| New | +$738K | ﹤0.01% | 5488 |
|
Susquehanna International Group's GTHX Position: Q2 2024 in Review
Susquehanna International Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 950,839 shares — an estimated $3.63M sold.
Susquehanna International Group first reported a position in GTHX in Q2 2019 and held it in 19 quarters. The position peaked at $4.81M in Q4 2023. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.
- Susquehanna International Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Susquehanna International Group sold 950,839 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $3.63M.
- Susquehanna International Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
- Susquehanna International Group's G1 Therapeutics, Inc. Common Stock position peaked at $4.81M in Q4 2023.
- 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.